Tags

Type your tag names separated by a space and hit enter

Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
Vaccine. 2022 07 30; 40(32):4348-4360.V

Abstract

Several population groups display an increased risk of severe disease and mortality following SARS-CoV-2 infection. These include those who are immunocompromised (IC), have a cancer diagnosis, human immunodeficiency virus (HIV) infection or chronic inflammatory disease including autoimmune disease, primary immunodeficiencies, and those with kidney or liver disease. As such, improved understanding of the course of COVID-19 disease, as well as the efficacy, safety, and benefit-risk profiles of COVID-19 vaccines in these vulnerable groups is paramount in order to inform health policy makers and identify evidence-based vaccination strategies. In this review, we seek to summarize current data, including recommendations by national health authorities, on the impact and benefit-risk profiles of COVID-19 vaccination in these populations. Moving forward, although significant efforts have been made to elucidate and characterize COVID-19 disease course and vaccine responses in these groups, further larger-scale and longer-term evaluation will be instrumental to help further guide management and vaccination strategies, particularly given concerns about waning of vaccine-induced immunity and the recent surge of transmission with SARS-CoV-2 variants of concern.

Links

PMC Free PDF

Authors+Show Affiliations

Moss P
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK; Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham B15 2TH, UK.
Berenbaum F
Sorbonne University, INSERM, AP-HP Saint-Antoine Hospital, Paris, France.
Curigliano G
Istituto Europeo di Oncologia, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Grupper A
Department of Nephrology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Berg T
Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, 04103 Leipzig, Germany.
Pather S
BioNTech SE, Mainz, Germany. Electronic address: shanti.pather@biontech.de.

MeSH

COVID-19COVID-19 VaccinesHumansPopulation GroupsSARS-CoV-2VaccinationVaccinesVulnerable Populations

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

35718592

Citation

Moss, Paul, et al. "Benefit-risk Evaluation of COVID-19 Vaccination in Special Population Groups of Interest." Vaccine, vol. 40, no. 32, 2022, pp. 4348-4360.
Moss P, Berenbaum F, Curigliano G, et al. Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest. Vaccine. 2022;40(32):4348-4360.
Moss, P., Berenbaum, F., Curigliano, G., Grupper, A., Berg, T., & Pather, S. (2022). Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest. Vaccine, 40(32), 4348-4360. https://doi.org/10.1016/j.vaccine.2022.05.067
Moss P, et al. Benefit-risk Evaluation of COVID-19 Vaccination in Special Population Groups of Interest. Vaccine. 2022 07 30;40(32):4348-4360. PubMed PMID: 35718592.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest. AU - Moss,Paul, AU - Berenbaum,Francis, AU - Curigliano,Giuseppe, AU - Grupper,Ayelet, AU - Berg,Thomas, AU - Pather,Shanti, Y1 - 2022/05/27/ PY - 2022/01/21/received PY - 2022/05/06/revised PY - 2022/05/22/accepted PY - 2022/6/20/pubmed PY - 2022/7/22/medline PY - 2022/6/19/entrez KW - COVID-19 KW - Immunocompromised KW - Kidney disease KW - Liver disease KW - Oncology KW - Special populations KW - Vaccination SP - 4348 EP - 4360 JF - Vaccine JO - Vaccine VL - 40 IS - 32 N2 - Several population groups display an increased risk of severe disease and mortality following SARS-CoV-2 infection. These include those who are immunocompromised (IC), have a cancer diagnosis, human immunodeficiency virus (HIV) infection or chronic inflammatory disease including autoimmune disease, primary immunodeficiencies, and those with kidney or liver disease. As such, improved understanding of the course of COVID-19 disease, as well as the efficacy, safety, and benefit-risk profiles of COVID-19 vaccines in these vulnerable groups is paramount in order to inform health policy makers and identify evidence-based vaccination strategies. In this review, we seek to summarize current data, including recommendations by national health authorities, on the impact and benefit-risk profiles of COVID-19 vaccination in these populations. Moving forward, although significant efforts have been made to elucidate and characterize COVID-19 disease course and vaccine responses in these groups, further larger-scale and longer-term evaluation will be instrumental to help further guide management and vaccination strategies, particularly given concerns about waning of vaccine-induced immunity and the recent surge of transmission with SARS-CoV-2 variants of concern. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/35718592/Benefit_risk_evaluation_of_COVID_19_vaccination_in_special_population_groups_of_interest_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓2 ↑132]

Related Citations

More